Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Ferrant

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|November 15, 2024
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapyPierre Sesques, Lionel Karlin, Emmanuel Massy, et al.
Hematological Oncology|July 11, 2024
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospitalCaroline Le Lan, Aurélien Belot, Camille Golfier, et al.
Leukemia & Lymphoma|November 1, 2021
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective studyGuillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D ResultsMazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood|February 14, 2018
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinibDavid Ghez, Anne Calleja, Caroline Protin, et al.
Blood Advances|April 19, 2022
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphomaEstelle Bourbon, Pierre Sesques, Morgane Gossez, et al.
Haematologica|March 10, 2018
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) studyGuillaume Cartron, Rémi Letestu, Caroline Dartigeas, et al.
Leukemia|April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood Advances|August 24, 2021
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specifiedEstelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, et al.
Cancer|April 15, 2026
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world studyArthur Coste, Nanthara Sritharan, Anne Lok, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|November 15, 2024
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapyPierre Sesques, Lionel Karlin, Emmanuel Massy, et al.
Hematological Oncology|July 11, 2024
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospitalCaroline Le Lan, Aurélien Belot, Camille Golfier, et al.
Leukemia & Lymphoma|November 1, 2021
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective studyGuillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D ResultsMazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood|February 14, 2018
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinibDavid Ghez, Anne Calleja, Caroline Protin, et al.
Blood Advances|April 19, 2022
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphomaEstelle Bourbon, Pierre Sesques, Morgane Gossez, et al.
Haematologica|March 10, 2018
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) studyGuillaume Cartron, Rémi Letestu, Caroline Dartigeas, et al.
Leukemia|April 24, 2025
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?Nicolas Gazeau, David Beauvais, Rémi Tilmont, et al.
Blood Advances|August 24, 2021
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specifiedEstelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, et al.
Cancer|April 15, 2026
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world studyArthur Coste, Nanthara Sritharan, Anne Lok, et al.
Pageof 5